Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Melanie Maerklin"'
Autor:
Ashish Goyal, Jens Bauer, Joschka Hey, Dimitris Papageorgiou, Ekaterina Stepanova, Michael Daskalakis, Marissa Dubbelaar, Boris Klimovich, Melanie Maerklin, Malte Roerden, Oliver Muecke, Hans-Georg Rammensee, Fabricio Loayza-Puch, Jeroen Krijgsveld, Michael Lübbert, Juliane Walz, Christoph Plass
Publikováno v:
HemaSphere, Vol 7, p e9967378 (2023)
Externí odkaz:
https://doaj.org/article/670908b88f5045ecba92c4ca4de6b02d
Autor:
Samuel J. Holzmayer, Sarah M. Greiner, Kuebra Kaban, Jonas S. Heitmann, Helmut R. Salih, Melanie Maerklin
Publikováno v:
Cancer Research. 82:2102-2102
Genetic loss of the transcription factor NFAT2 (NFATc1), known as important player in lymphocyte development, causes an aggressive course of CLL, as it enhances BCR signaling and leads to highly malignant and proliferative disease (Märklin et al. Na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ca61c9cf7155c01c07d2c23d69b88ad
https://doi.org/10.1158/1538-7445.am2022-2102
https://doi.org/10.1158/1538-7445.am2022-2102
Autor:
Martina S. Lutz, Boris Klimovich, Stefanie Maurer, Jonas S. Heitmann, Melanie Maerklin, Latifa Zekri, Gundram Jung, Helmut R. Salih, Clemens Hinterleitner
Publikováno v:
Cancer Research. 82:2859-2859
Immunotherapeutic strategies such as T cell-recruiting bispecific antibodies (bsAb), chimeric antigen receptor (CAR) T cells, and immune checkpoint inhibition have revolutionized oncological treatment. However, many patients do not respond to treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15f3729671a5ef5aa9140d380e926dee
https://doi.org/10.1158/1538-7445.am2022-2859
https://doi.org/10.1158/1538-7445.am2022-2859
Autor:
Martina S. Lutz, Bastian J. Schmied, Fabian Riegg, Latifa Zekri, Jonas S. Heitmann, Melanie Maerklin, Martin Pfluegler, Gundram Jung, Helmut R. Salih
Publikováno v:
Cancer Research. 82:2860-2860
After diagnosis, a primary goal of treatment in acute myeloid leukemia (AML) is to achieve a morphological complete remission (CR) by induction chemotherapy. However, about half of the patients in CR show remaining minimal residual disease (MRD), whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aa5cb8ca54f3a9d6a3c28749f0a202d
https://doi.org/10.1158/1538-7445.am2022-2860
https://doi.org/10.1158/1538-7445.am2022-2860
Autor:
Juliane S. Walz, Felix Ruoff, Sigrun Smola, Jens Gottlieb, Melanie Maerklin, Matthias Becker, Hans-Georg Rammensee, Anne Zeck, André Karch, Daniel Junker, Andreas Peter, Jonas S. Heitmann, Ulrich Rothbauer, Thomas O. Joos, Annika Nelde, Markus Cornberg, Monika Strengert, Julia Haering, Frank Weise, Tobias Kerrinnes, Gérard Krause, Thomas Illig, Armin Baillot, Katja Schenke-Layland, Bjoern Traenkle, Sebastian Hoerber, Tamam Bakchoul, Stefan Lohse, Simon Fink, Philipp D. Kaiser, Klaus Berger, Nicole Schneiderhan-Marra, Markus F. Templin, Heiko Dinter
Given the importance of the humoral immune response to SARS-CoV-2 as a global benchmark for immunity, a detailed analysis is needed to monitor seroconversion in the general population, understand manifestation and progression of COVID-19 disease, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73fc66df51310a422ca5bd9449bc3abc
https://doi.org/10.1101/2020.07.17.20156000
https://doi.org/10.1101/2020.07.17.20156000
Autor:
Anjana Rao, Felicia Truckenmueller, Melanie Maerklin, Manuela Ganser, Martin R Mueller, Hans-Georg Kopp, Lothar Kanz, Stefan Wirths, Jonas S. Heitmann
Publikováno v:
Journal of Clinical Oncology. 33:7019-7019
7019 Background: NFAT2 is a highly phosphorylated transcription factor which regulates developmental and activation programs in diverse cell types. CLL constitutes a heterogeneous disease with some...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a452c54ecfd1e650cbd85198918d35b
https://doi.org/10.1200/jco.2015.33.15_suppl.7019
https://doi.org/10.1200/jco.2015.33.15_suppl.7019
Autor:
Melanie Maerklin, Hans-Georg Kopp, Martin R Mueller, Lothar Kanz, Jonas S. Heitmann, Juliane S. Stickel, Stefan Wirths, Alexandra Poljak, Bettina Hackl
Publikováno v:
Journal of Clinical Oncology. 31:7019-7019
7019 Background: CLL is a malignancy of mature B cells and constiututes the most common leukemia in adults. It is characterized by a progressive accumulation of clonal B cells, which coexpress CD19, CD23 and CD5. NFAT is a family of highly phosphoryl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::655a661895624dc90624a2b72e2e1384
https://doi.org/10.1200/jco.2013.31.15_suppl.7019
https://doi.org/10.1200/jco.2013.31.15_suppl.7019